$AQXP (Aquinox Pharmaceuticals Inc.)

$AQXP {{ '2015-08-13T12:19:11+0000' | timeago}} • SEC

$AQXP Form 4: On Aug. 10, 2015, Pfizer Inc. disposed of 259,927 of AQXP’s shares in multiple transactions at prices ranging from a low of $20 to a high of $41.46. Pfizer now owns 975,403 of AQXP’s shares.

$RMD {{ '2018-01-22T22:00:14+0000' | timeago}} • Announcement

Hurt by one-time charges related to the US tax reform, $RMD reported 88% decline in 2Q18 earnings to $9.5MM, or 7 cents per share. Excluding these charges, net income rose 37% to $1 during the quarter. Meanwhile, revenue jumped 13% to $601.3MM.

$RMD {{ '2018-01-22T21:48:59+0000' | timeago}} • Infographic

$RMD ResMed Inc. Earnings AlphaGraphic: Q2 2018 Highlights

$CELG {{ '2018-01-22T13:26:32+0000' | timeago}} • Announcement

Last week's rumor becomes reality. $CELG to acquire its strategic partner $JUNO for $9Bil. Juno Therapeutics, which had already skyrocketed nearly 50% in the last week, has increased more than 25% today in pre-market from Jan. 19th closing price of $67.81. Celgene expects that this deal will help it to boost the revenue generation beyond 2020.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$DPLO {{ '2018-01-05T14:38:12+0000' | timeago}} • Announcement

$DPLO, a provider of specialty pharmacy services, has appointed Jeff Park as Interim CEO. Jeff, a member of Diplomat's board, will succeed Phil Hagerman who has retired. Ben Wolin, independent lead director, has been named Chairman of the board of directors. Hagerman will continue to serve as a director and assume the role of Chairman Emeritus.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$DPLO {{ '2017-12-21T16:45:43+0000' | timeago}} • Announcement

$DPLO completed acquisition of Leehar Distributors LLC, doing business as LDI Integrated Pharmacy Services, from Nautic Partners, Oak HC/FT Partners, and LDI management. $DPLO also entered into new $800MM senior secured credit facilities.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$CYH {{ '2017-12-14T13:11:35+0000' | timeago}} • Announcement

$CYH elected Michael Dinkins and Ranga Krishnan to the Board of Directors for terms that will expire at the 2018 Annual Meeting of Stockholders. As part of a settlement in a derivative action lawsuit finalized in January 2017, the company sought the names of prospective candidates for the BoD from its stockholders.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

Recent Transcripts

IMUC (ImmunoCellular Therapeutics, Ltd.)
Tuesday, November 21 2017 - 10:00pm
OCUL (Ocular Therapeutix, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
DPLO (Diplomat Pharmacy, Inc.)
Monday, November 6 2017 - 10:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
CYH (Community Health Systems, Inc.)
Thursday, November 2 2017 - 3:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AET (Aetna Inc.)
Tuesday, October 31 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
OCUL (Ocular Therapeutix, Inc.)
Tuesday, August 8 2017 - 9:00pm
OMER (Omeros Corporation)
Tuesday, August 8 2017 - 8:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm
CVS (CVS Health Corporation)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm

AlphaGraphics you may like